Artax Biopharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2013-01-01
- Employees
- 1
- Market Cap
- -
Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis
Phase 1
Active, not recruiting
- Conditions
- PsoriasisPlaque Psoriasis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Artax Biopharma Inc
- Target Recruit Count
- 31
- Registration Number
- NCT05725057
- Locations
- 🇬🇧
Accellacare Northamptonshire, Corby, United Kingdom
🇬🇧MEU, Manchester, United Kingdom
🇬🇧Accellacare North London, Northwood, United Kingdom
A Study of the Safety, Tolerability, Pharmacokinetics and Food Effect After Single and Multiple Ascending Oral Doses
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Artax Biopharma Inc
- Target Recruit Count
- 64
- Registration Number
- NCT05218434
- Locations
- 🇬🇧
Simbec-Orion, Merthyr Tydfil, United Kingdom
Potential Food Effect And Repeated Dosing of AX-024.HCl In Healthy Subjects
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2016-02-09
- Lead Sponsor
- Artax Biopharma Inc
- Target Recruit Count
- 32
- Registration Number
- NCT02546635
- Locations
- 🇬🇧
Simbec Research Ltd, Merthyr Tydfil, Cardiff Road, United Kingdom
Safety Study of Immune System Modulator for Autoimmune Diseases
- First Posted Date
- 2014-09-18
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- Artax Biopharma Inc
- Target Recruit Count
- 18
- Registration Number
- NCT02243683
- Locations
- 🇬🇧
Simbec Research Ltd, Merthyr Tydfil, Cardiff Road, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath